300 results found.

Healthy Clinical Trial using BI 655075; Placebo to dose; Placebo to BI 655075; dabigatran

Boehringer Ingelheim - Recruiting 20 years to 45 years.
- Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2)..
BI 655075; Placebo to dose; Placebo to BI 655075; dabigatran

Atopic Dermatitis Clinical Trial using MK-8226; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Randomized, Double-Blinded, Placebo-Controlled Multiple Rising Dose Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MK-8226 in Patients With Moderate to Severe Atopic Dermatitis.
MK-8226; Placebo

Pediatric Crohn's Disease Clinical Trial using TA-650

Mitsubishi Tanabe Pharma Corporation - Recruiting 6 years to 17 years.
- Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Crohn's Disease.
TA-650

Hepatitis C Clinical Trial using MK-5172

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- An Open-label, 3-Part, Multiple Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-5172.
MK-5172

Hemorrhage Clinical Trial using BI 655075; Placebo

Boehringer Ingelheim - Recruiting 45 years to 80 years.
- Randomised, Double-blind, Placebo-controlled, Two-way Cross-over Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655075 and to Establish the Efficacy of BI 655075 in Reversal of Dabigatran Anticoagulant Activity in Volunteers.
BI 655075; Placebo

Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Onc Clinical Trial using AMG 232

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors.
AMG 232

Chemotherapy-induced Nausea and Vomiting Clinical Trial using Fosaprepitant 150 mg; Fosaprepitant 60 mg; Fosaprepitant 20 mg; Placebo Fosaprepitant; Ondansetron

Merck Sharp & Dohme Corp. - Recruiting N/A to 17 years.
- A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy.
Fosaprepitant 150 mg; Fosaprepitant 60 mg; Fosaprepitant 20 mg; Placebo Fosaprepitant; Ondansetron

Diabetes Mellitus, Type 2 Clinical Trial using Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Janssen Research & Development, LLC - Recruiting 10 years to 17 years.
- Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ò10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin.
Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Hereditary Angioedema (HAE) Clinical Trial using Icatibant (30 mg)

Shire Development LLC - Recruiting 18 years to 55 years.
- An Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers.
Icatibant (30 mg)

Candidemia Clinical Trial using anidulafungin; fluconazole

Pfizer - Recruiting 1 Month to 17 years.
- A Prospective, Open-Label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidaemia.
anidulafungin; fluconazole

Post-Operative Nausea, or Post-Operative Vomiting Clinical Trial using Aprepitant; Placebo to match aprepitant; Ondansetron; Placebo to match ondansetron

Merck Sharp & Dohme Corp. - Recruiting N/A to 17 years.
- A Phase IIb, Partially-Blinded, Randomized, Active Comparator- Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting.
Aprepitant; Placebo to match aprepitant; Ondansetron; Placebo to match ondansetron

Chronic Hepatitis C, Hepatitis C Virus, or Compensated Cirrhosis Clinical Trial using ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

AbbVie - Recruiting 18 years to 70 years.
- A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
ABT-493; ABT-530; ABT-450/r/ABT-267; ABT-333; Ribavirin (RBV)

HIV, HIV Infections, or Pregnancy Clinical Trial using TMC114 (darunavir); ritonavir; TMC125 (etravirine); TMC278 (rilpivirine)

Janssen Scientific Affairs, LLC - Recruiting 18 years or older.
- A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir/Ritonavir and/or Etravirine and Rilpivirine in HIV-1 Infected Pregnant Women.
TMC114 (darunavir); ritonavir; TMC125 (etravirine); TMC278 (rilpivirine)

Hepatitis Clinical Trial using MK-5172

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients.
MK-5172

Hereditary Angioedema Clinical Trial using icatibant

Shire Development LLC - Recruiting 2 years to 17 years.
- A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents With Hereditary Angioedema.
icatibant

Healthy Clinical Trial using 0.15 mg PF-06649751; 0.5 mg PF-06649751; 1.5 mg PF-06649751; 1.0 mg PF-06649751; TBD mg PF-06649751

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06649751 In Healthy Subjects.
0.15 mg PF-06649751; 0.5 mg PF-06649751; 1.5 mg PF-06649751; 1.0 mg PF-06649751; TBD mg PF-06649751

Pharmacokinetics, Cardiopulmonary Bypass, or Children Clinical Trial

Duke University - Recruiting N/A to 2 years.
- Pharmacokinetics of Dexmedetomidine in Children During Cardiopulmonary Bypass (CPB).

Polyarticular-course Juvenile Idiopathic Arthritis (JIA) Clinical Trial using Certolizumab Pegol (CZP)

UCB, Inc. - Recruiting 2 years to 17 years.
- A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
Certolizumab Pegol (CZP)

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Perinatal Asphyxia Clinical Trial using 2-Iminobiotin; Placebo

Neurophyxia B.V. - Recruiting N/A to 6 Hours.
- A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) in Neonates With ò36 Weeks GA With Moderate to Severe Perinatal Asphyxia.
2-Iminobiotin; Placebo

Infection Clinical Trial using Colistin

University of Zurich - Recruiting 18 years or older.
- Colistimethate and Colistin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy (CRRT).
Colistin

Myelodysplastic Syndromes, or Leukemia, Myelomonocytic, Chronic Clinical Trial using Azacitidine; Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Ineligible for High-intensity Therapy.
Azacitidine; Volasertib

Arthritis, Rheumatoid, or Healthy Clinical Trial using BI 655064 medium dose; BI 655064 high dose; Placebo; BI 655064 low dose

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy.
BI 655064 medium dose; BI 655064 high dose; Placebo; BI 655064 low dose

Leukemia, or Neoplasms Clinical Trial using volasertib

Boehringer Ingelheim - Recruiting 2 years to 17 years.
- Open, Non-controlled, Dose Escalating Phase I Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Tolerability and Toxicity of Volasertib in Paediatric Patients From 2 Years to Less Than 18 Years of Age With Acute Leukaemia or Advanced Solid Tumour, for Whom no Effective Treatment is Known.
volasertib

Crohn Disease Clinical Trial using BI 655066 (high dose); BI 655066 (low dose); BI 655066 one dose; placebo dose

Boehringer Ingelheim - Recruiting 18 years to 75 years.
- A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066, an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are na‹ve to, or Were Previously Treated With Anti-TNF Therapy..
BI 655066 (high dose); BI 655066 (low dose); BI 655066 one dose; placebo dose

Healthy Clinical Trial using BI 1181181; BI 1181181, R; BI 1181181, T2; Placebo to BI 1181181; BI 1181181, T1

Boehringer Ingelheim - Recruiting 18 years to 50 years.
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability and the Effect of Food on the Pharmacokinetics of BI 1181181(Open-label, Randomised, Three-way Cross-over Design).
BI 1181181; BI 1181181, R; BI 1181181, T2; Placebo to BI 1181181; BI 1181181, T1

Diabetes Mellitus, Type 1 Clinical Trial using Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Boehringer Ingelheim - Recruiting 18 years to 65 years.
- A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2).
Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Healthy Clinical Trial using BI 113608; Placebo

Boehringer Ingelheim - Recruiting 20 years to 45 years.
- Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 113608 in Healthy Male Asian and Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups).
BI 113608; Placebo

Healthy Clinical Trial using BI 1034020; Placebo to BI 1034020

Boehringer Ingelheim - Recruiting 18 years to 40 years.
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study).
BI 1034020; Placebo to BI 1034020

Arthritis, Rheumatoid Clinical Trial using BI 695500; rituximab

Boehringer Ingelheim - Recruiting 18 years to 80 years.
- Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial..
BI 695500; rituximab

Lymphoma, Follicular Clinical Trial using BI 695500; MabThera

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma.
BI 695500; MabThera

Leukemia, Myeloid, Acute Clinical Trial using decitabine iv; volasertib iv infusion

Boehringer Ingelheim - Recruiting 60 years or older.
- An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia.
decitabine iv; volasertib iv infusion

Purpura, Thrombocytopenic, Idiopathic Clinical Trial using BI 655064

Boehringer Ingelheim - Recruiting 18 years or older.
- Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura..
BI 655064

Healthy Volunteers Clinical Trial using JNJ-38877618: Part 1a; JNJ-38877618: Part 1b; JNJ-38877618: Part 1c (optional); JNJ-38877618: Part 2; JNJ-38877618: Part 3; JNJ-38877618: Part 4 (optional); Placebo: Parts 1a, 2, 3, and 4 (optional)

Janssen Cilag N.V./S.A. - Recruiting 18 years to 65 years.
- A Double Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Subjects.
JNJ-38877618: Part 1a; JNJ-38877618: Part 1b; JNJ-38877618: Part 1c (optional); JNJ-38877618: Part 2; JNJ-38877618: Part 3; JNJ-38877618: Part 4 (optional); Placebo: Parts 1a, 2, 3, and 4 (optional)

Type 1 Diabetes Mellitus Clinical Trial using Secukinumab; Placebo

Novartis - Recruiting 8 years to 35 years.
- A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus (T1D).
Secukinumab; Placebo

Chronic Obstructive Pulmonary Disease (COPD) With Cachexia Clinical Trial using Placebo; BYM338

Novartis - Recruiting 40 years to 80 years.
- A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia.
Placebo; BYM338

Crohn's Disease Clinical Trial using AMG 139

Amgen - Recruiting 18 years to 55 years.
- A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease.
AMG 139

Persistent Pulmonary Hypertension of the Newborn Clinical Trial using 1 dose of sildenafil

University of North Carolina, Chapel Hill - Recruiting N/A to 364 Days.
- Pharmacokinetics of Sildenafil in Premature Infants.
1 dose of sildenafil

Venous Thromboembolism Clinical Trial using dabigatran etexilate

Boehringer Ingelheim - Recruiting 1 year to 2 years.
- Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89.
dabigatran etexilate

Sciatica, or Lumbosacral Radiculopathy Clinical Trial using MDT-15

Medtronic Spinal and Biologics - Recruiting 18 years or older.
- An Open-Label, Sequential, Dose Escalation Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy.
MDT-15

Normal Hepatic Function, or Impaired Hepatic Function Clinical Trial using LDK378

Novartis - Recruiting 18 years to 70 years.
- A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDK378 in Subjects With Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
LDK378

Effect of Atorvastatin on the Pharmacokinetics of Lomitapide Clinical Trial using lomitapide; Atorvastatin

Aegerion Pharmaceuticals, Inc. - Recruiting 18 years to 55 years.
- A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Atorvastatin, a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Subjects.
lomitapide; Atorvastatin

Healthy Clinical Trial using lomitapide; EE/norgestimate

Aegerion Pharmaceuticals, Inc. - Recruiting 18 years to 40 years.
- A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects.
lomitapide; EE/norgestimate

Prostatic Neoplasms Clinical Trial using BAY2010112

Bayer - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY2010112 Given Once Daily by Subcutaneous Administration in Subjects With Castration-resistant Prostate Cancer.
BAY2010112

Solid Tumour Clinical Trial using GDC-0994

Genentech - Recruiting 18 years or older.
- An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors.
GDC-0994

Neoplasms Clinical Trial using MEHD7945A; cobimetinib

Genentech - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MEHD7945A and GDC-0973 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH MUTANT KRAS.
MEHD7945A; cobimetinib

Non-Small Cell Lung Cancer, Ovarian Cancer Clinical Trial using DNIB0600A

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
DNIB0600A

Ovarian Cancer, Pancreatic Cancer Clinical Trial using DMUC5754A

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer.
DMUC5754A

Head and Neck Cancer Clinical Trial using MEHD7945A; cisplatin; 5-FU; carboplatin; paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
MEHD7945A; cisplatin; 5-FU; carboplatin; paclitaxel

Multiple Myeloma Clinical Trial using DFRF4539A

Genentech - Recruiting 18 years or older.
- An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma.
DFRF4539A

Ovarian Cancer, Pancreatic Cancer Clinical Trial using DMOT4039A

Genentech - Recruiting 18 years or older.
- A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer.
DMOT4039A

Healthy Volunteers Clinical Trial using LY2605541; Insulin Lispro

Eli Lilly and Company - Recruiting 21 years to 65 years.
- A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects.
LY2605541; Insulin Lispro

Healthy Clinical Trial using PF-06678552 or Placebo

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Fed And Fasted Administration Of Single Escalating Oral Doses In Healthy Subjects.
PF-06678552 or Placebo

Neoplasms Clinical Trial using GDC-0973; GDC-0068

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors.
GDC-0973; GDC-0068

Lymphoma, Solid Tumour Clinical Trial using GDC-0575; gemcitabine

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma.
GDC-0575; gemcitabine

Breast Cancer Clinical Trial using GDC-0032; Docetaxel; Paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer.
GDC-0032; Docetaxel; Paclitaxel

Anemia, or Kidney Failure, Chronic Clinical Trial using Sotatercept

Celgene Corporation - Recruiting 18 years or older.
- A Phase 2 Multicenter, Randomized, Open-Label , Multiple-Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects With End-Stage Kidney Disease on Hemodialysis Switched From Erythropoiesis Stimulating Agents With Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group, Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: To Evaluate the Pharmacokinetics, Safety, Tolerability, Efficacy, Dosing Regimen, and Pharmacodynamics of Sotatercept.
Sotatercept

Malignant Melanoma Clinical Trial using DEDN6526A

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma.
DEDN6526A

Lymphocytic Leukemia, Chronic Clinical Trial using GDC-0199 (ABT-199); rituximab [MabThera/Rituxan]; bendamustine

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Bendamustine/Rituximab (BR) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia.
GDC-0199 (ABT-199); rituximab [MabThera/Rituxan]; bendamustine

Neoplasms Clinical Trial using BAY1125976

Bayer - Recruiting 18 years or older.
- A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors.
BAY1125976

Solid Cancers Clinical Trial using Vismodegib

Genentech - Recruiting 18 years or older.
- A Phase Ib Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function.
Vismodegib

Advanced Cancer Clinical Trial using crizotinib

Pfizer - Recruiting 18 years or older.
- A Phase I Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Crizotinib In Advanced Cancer Patients.
crizotinib

Kidney Failure, Chronic, or Renal Insufficiency, Chronic Clinical Trial using LY2409021

Eli Lilly and Company - Recruiting 18 years to 85 years.
- Pharmacokinetics of LY2409021 Following Administration to Subjects With Varying Degrees of Renal Function.
LY2409021

Chronic Plaque-type Psoriasis Clinical Trial using CJM112; Secukinumab; Placebo

Novartis - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients.
CJM112; Secukinumab; Placebo

Solid Cancers Clinical Trial using MPDL3280A

Genentech - Recruiting 18 years or older.
- A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies.
MPDL3280A

Infections Clinical Trial

Duke University - Recruiting N/A to 18 years.
- CSF Pharmacokinetics of Antimicrobials in Children.

Pancreatic Cancer Clinical Trial using Gemcitabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas.
Gemcitabine

Paediatric Antimicrobial Pharmacokinetics Clinical Trial

St George's, University of London - Recruiting N/A to 15 years.
- Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study.

Pancreatic Cancer Clinical Trial using Gemcitabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Tissue Pharmacokinetics of Intraoperative Gemcitabine in Adenocarcinoma of the Pancreas After Preoperative Chemoradiation Therapy.
Gemcitabine

Alzheimer's Disease Clinical Trial using ITI-007; Placebo

Intra-Cellular Therapies, Inc. - Recruiting 65 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia..
ITI-007; Placebo

Hypoglycemia Clinical Trial using G-Pen Mini™ (glucagon injection)

Xeris Pharmaceuticals - Recruiting 18 years to 30 years.
- A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM).
G-Pen Mini™ (glucagon injection)

Mild to Moderate Atopic Dermatitis Clinical Trial using SB011, 2 % (Water/Oil/Water) emulsion of hgd40; Multiple W/O/W formulation, active ingredient-free vehicle

Sterna Biologicals GmbH & Co. KG - Recruiting 18 years to 60 years.
- A Phase IIa, Single-centre, Randomised, Vehicle Controlled, Double-blind Trial for Assessment of Efficacy, Safety and Tolerability of the Topical Formulation SB011 Containing a Human GATA-3 Specific DNAzyme and of Systemic Absorption of hgd40 Following Application to Lesional Skin in Patients With Atopic Eczema.
SB011, 2 % (Water/Oil/Water) emulsion of hgd40; Multiple W/O/W formulation, active ingredient-free vehicle

Migraine Clinical Trial using AMG 333; Placebo

Amgen - Recruiting 18 years to 55 years.
- A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Subjects With Migraines..
AMG 333; Placebo

Mild-Moderate Alzheimer's Disease, or Healthy Elderly Clinical Trial using MEDI1814 for IV injection; MEDI1814 for Subcutaneous Injection; IV Placebo; Placebo for Subcutaneous Injection

AstraZeneca - Recruiting 55 years to 85 years.
- A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease..
MEDI1814 for IV injection; MEDI1814 for Subcutaneous Injection; IV Placebo; Placebo for Subcutaneous Injection

Pharmacokinetics Clinical Trial using Beclomethasone dipropionate BAI; Beclomethasone dipropionate MDI

Teva Pharmaceutical Industries - Recruiting 18 years to 45 years.
- A Randomized, Open-Label, 3-Period Crossover, Single-Dose Clinical Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Beclomethasone Dipropionate (160 and 320 mcg) Delivered Via Breath-Actuated Inhaler (BAI) and Metered-Dose Inhaler (MDI) in Healthy Adult Subjects.
Beclomethasone dipropionate BAI; Beclomethasone dipropionate MDI

Hepatocellular Carcinoma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects With or Without Chronic Viral Hepatitis.
Nivolumab

Ewing Family of Tumors, Rhabdomyosarcoma Clinical Trial using Lipegfilgrastim

Teva Pharmaceutical Industries - Recruiting 2 years to 17 years.
- Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100æg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma.
Lipegfilgrastim

Opioid Use, Unspecified With Other Opioid-induced Disorder Clinical Trial using Methylnaltrexone

University of Zurich - Recruiting 18 years or older.
- Pharmacokinetics of Once Daily Subcutaneous Methylnaltrexone in Neurointensive Care Patients With High Dose Sufentanil Analgosedation.
Methylnaltrexone

Hematologic Malignancies, or Solid Tumors Clinical Trial using omacetaxine mepesuccinate

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors.
omacetaxine mepesuccinate

Advanced Solid Malignancies Clinical Trial using AZD2014

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTor Kinase Inhibitor AZD2014 Administered Orally to Patients With Advanced Solid Malignancies.
AZD2014

Healthy, or HIV Clinical Trial using 1 mg/kg, single dose IV administration of 3BNC117; 3 mg/kg, single dose IV administration of 3BNC117; 10 mg/kg, single dose IV administration of 3BNC117

Rockefeller University - Recruiting 18 years to 65 years.
- A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers.
1 mg/kg, single dose IV administration of 3BNC117; 3 mg/kg, single dose IV administration of 3BNC117; 10 mg/kg, single dose IV administration of 3BNC117

Cancer Metastatic to the Liver, Hepatocellular Carcinoma That is Clinical Trial using PV-10 (10% rose bengal disodium)

Provectus Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant.
PV-10 (10% rose bengal disodium)

HIV-1 Infection Clinical Trial using BMS-955176; Placebo matching with BMS-955176; Atazanavir; Ritonavir; Tenofovir; Emtricitabine

Bristol-Myers Squibb - Recruiting 18 years to 55 years.
- Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects.
BMS-955176; Placebo matching with BMS-955176; Atazanavir; Ritonavir; Tenofovir; Emtricitabine

Chagas Disease Clinical Trial using Nifurtimox (BAYa2502) (4 x 30 mg tablet); Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water); Nifurtimox (BAYa2502) (120 mg tablet)

Bayer - Recruiting 18 years to 45 years.
- Open Label, Randomized, Single Dose Cross-over Study to Assess Bioequivalence Between Single 120 mg Nifurtimox Tablet and Four 30 mg Nifurtimox Tablets Administered Orally, Following High Calorie/High Fat Meal to Adult Male and Female Patients Suffering From Chronic Chagas' Disease and to Determine the Pharmacokinetics of Nifurtimox Tablets Administered Orally, in a Form of Aqueous Slurry.
Nifurtimox (BAYa2502) (4 x 30 mg tablet); Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water); Nifurtimox (BAYa2502) (120 mg tablet)

Hematological Malignancies Clinical Trial using KPT-330

NPM Pharma Inc. - Recruiting 18 years or older.
- A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Malignancies.
KPT-330

Oncology, BRCA Mutated, High Grade Serous Ovarian Cancer, or BRCA Clinical Trial using Veliparib

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors.
Veliparib

Non-Hodgkin's Lymphoma Clinical Trial using ABT-199; Ketoconazole

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199.
ABT-199; Ketoconazole

Non-Hodgkin's Lymphoma Clinical Trial using ABT-199; Rifampin

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199.
ABT-199; Rifampin

Inflammation, or Rheumatoid Arthritis Clinical Trial using NNC0215-0384; placebo

Novo Nordisk - Recruiting 18 years to 75 years.
- A Randomised, Placebo-controlled, Double-blind Within Cohort, Dose Escalation, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered Subcutaneously to Subjects With Moderate to Severe Rheumatoid Arthritis.
NNC0215-0384; placebo

Hemophilia A Clinical Trial using PF-05280602

Pfizer - Recruiting 18 years to 64 years.
- An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics / Pharmacodynamics Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors.
PF-05280602

Pulmonary Arterial Hypertension Clinical Trial using Tadalafil- Tablet

Eli Lilly and Company - Recruiting 6 Months to 17 years.
- A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension.
Tadalafil- Tablet

Tumor or Lymphoma Clinical Trial using JNJ-42756493

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
JNJ-42756493

Primary Hemophagocytic Lymphohistiocytosis Clinical Trial using NI-0501

NovImmune SA - Recruiting N/A to 18 years.
- A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis Which Has Reactivated..
NI-0501

Healthy Clinical Trial using PF-06480605; Placebo

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.
PF-06480605; Placebo

Healthy Clinical Trial using 3 mg PF-06412562; 10 mg PF-06412562; 25 mg PF-06412562; PF-06412562 TBD mg

Pfizer - Recruiting 18 years to 55 years.
- Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of PF-06412562 In Healthy Subjects.
3 mg PF-06412562; 10 mg PF-06412562; 25 mg PF-06412562; PF-06412562 TBD mg

Acquired Immune Deficiency Syndrome (AIDS), or HIV Infections Clinical Trial using E/C/F/TAF

Gilead Sciences - Recruiting 12 years to 17 years.
- A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents.
E/C/F/TAF

Advanced Cancer Clinical Trial using LY2874455

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer..
LY2874455

Cerebral Amyloid Angiopathy Clinical Trial using Ponezumab; placebo

Pfizer - Recruiting 55 years to 80 years.
- A Phase 2, Randomized, Double Blind Placebo Controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of PF-04360365 (Ponezumab) in Adult Subjects With Probable Cerebral Amyloid Angiopathy.
Ponezumab; placebo

Healthy Clinical Trial using PF-06273340; Placebo

Pfizer - Recruiting 18 years to 75 years.
- A Phase 1, Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Doses of PF-06273340 in Healthy Subjects.
PF-06273340; Placebo

COPD, or Healthy Subjects Clinical Trial using AZD7624; Placebo to match

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD.
AZD7624; Placebo to match

Colitis, Ulcerative Clinical Trial using Golimumab

Janssen Research & Development, LLC - Recruiting 2 years to 17 years.
- A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFà Antibody, in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis.
Golimumab

Healthy Clinical Trial using PF-06372865 or Placebo; PF-06372865 or Placebo or Lorazepam

Pfizer - Recruiting 18 years to 55 years.
- A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06372865 in Healthy Male and Female Subjects.
PF-06372865 or Placebo; PF-06372865 or Placebo or Lorazepam

Growth Hormone Disorder, or Growth Hormone Deficiency in Children Clinical Trial using NNC0195-0092; somatropin

Novo Nordisk - Recruiting 6 years to 13 years.
- A Randomised, Open-labelled, Active-controlled, Multinational, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (NNC0195-0092) Compared to Daily Dosing of Norditropinr SimpleXxr in Children With Growth Hormone Deficiency.
NNC0195-0092; somatropin

Systemic Infections Clinical Trial using CAZ-AVI

AstraZeneca - Recruiting 3 Months to 17 years.
- A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection.
CAZ-AVI

Healthy Volunteers Clinical Trial using LY2835219

Eli Lilly and Company - Recruiting 18 years to 65 years.
- Effect of Food on the Pharmacokinetics of LY2835219 in Healthy Subjects.
LY2835219

Macular Degeneration Clinical Trial using RO6867461

Hoffmann-La Roche - Recruiting 50 years or older.
- A Multiple-Center, Non-Randomized, Open-Label, Single-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration..
RO6867461

Neoplasms Clinical Trial using zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase Ia/Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotininb (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-positive Solid Tumors of Ephitelian Cell Origin.
zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Neoplasms Clinical Trial using RO5509554; paclitaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors..
RO5509554; paclitaxel

Neoplasms Clinical Trial using Vemurafenib; Cobimetinib; Onartuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES.
Vemurafenib; Cobimetinib; Onartuzumab

Lymphoma Clinical Trial using MabThera/Rituxan; Standard chemotherapy

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Single Arm, Multicentre, Phase IIIb Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL).
MabThera/Rituxan; Standard chemotherapy

Major Depressive Disorder Clinical Trial using LY03005; Placebo

Luye Pharma Group Ltd. - Recruiting 18 years to 45 years.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005.
LY03005; Placebo

Neoplasms Clinical Trial using RO5503781; posaconazole

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTIPLE-CENTER, OPEN-LABEL CLINICAL PHARMACOLOGY STUDY WITH RO5503781, AN MDM2 ANTAGONIST, IN PATIENTS WITH SOLID TUMORS TO DETERMINE: PART 1 ONE-SEQUENCE, 2-PERIOD CROSSOVER DESIGN TO INVESTIGATE THE EFFECT OF POSACONAZOLE, A STRONG CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RO5503781 PART 2 A RANDOMIZED, SINGLE DOSE, 3 PERIOD CROSSOVER DESIGN TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF TWO NEW RO5503781 TABLET FORMULATIONS FOLLOWING ORAL ADMINISTRATION.
RO5503781; posaconazole

Healthy Volunteer Clinical Trial using GDC-0032

Genentech - Recruiting 18 years to 55 years.
- A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects.
GDC-0032

Non-Hodgkin's Lymphoma Clinical Trial using Mabthera intravenous; MabThera subcutaneous

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-stage Phase III, International, Multi-center, Randomized, Controlled, Open-label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV.
Mabthera intravenous; MabThera subcutaneous

Narcolepsy Clinical Trial using Armodafinil

Teva Pharmaceutical Industries - Recruiting 6 years to 17 years.
- A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy.
Armodafinil

Solid Tumours Clinical Trial using selumetinib; rifampicin

AstraZeneca - Recruiting 18 years to 45 years.
- A Phase I Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inducer Rifampicin on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years.
selumetinib; rifampicin

Healthy Clinical Trial using PF-05230907; Placebo for PF-05230907

Pfizer - Recruiting 18 years to 35 years.
- A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers.
PF-05230907; Placebo for PF-05230907

Solid Tumours Clinical Trial using Pharmacokinetic sampling; Olaparib tablet dosing; Itraconazole

AstraZeneca - Recruiting 18 years or older.
- A Non-randomised, Open-label, Sequential, Three-part, Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation, and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours.
Pharmacokinetic sampling; Olaparib tablet dosing; Itraconazole

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; acenocoumarol

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; acenocoumarol

Acromegaly, Pituitary Gigantism Clinical Trial using SOM230LAR

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism.
SOM230LAR

Acute Myeloid Leukemia (AML), or Acute Lymphocytic Leukemia (ALL) Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia.
CB-839

Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy, Clinical Trial using Intermittent dosing of AZD5363

AstraZeneca - Recruiting 18 years or older.
- A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS).
Intermittent dosing of AZD5363

Hepatic Insufficiency Clinical Trial using MK-8742

Merck Sharp & Dohme Corp. - Recruiting 18 years to 75 years.
- A Three-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-8742.
MK-8742

Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Mac Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies.
CB-839

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CL Clinical Trial using Administration of AZD6738

AstraZeneca - Recruiting 18 years or older.
- A Two-part Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of Multiple Ascending Doses of AZD6738 in Patients With Relapsed/Refractory B Cell Malignancies With Expansion to Patients With Prospectively Identified 11q-deleted or ATM-deficient, Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL).
Administration of AZD6738

Osteoarthritis Pain Clinical Trial using Etoricoxib 75 mg 4% DMSO Gel; Etoricoxib 75 mg 4% PG Gel; Etoricoxib 150 mg 4% DMSO Gel; Etoricoxib 150 mg 4% PG Gel; Matching Placebo to Etoricoxib 150 mg 4% DMSO Gel; Matching Placebo to Etoricoxib 150 mg 4% PG Gel

Merck Sharp & Dohme Corp. - Recruiting 40 years or older.
- A Study to Assess the Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Osteoarthritis Patients.
Etoricoxib 75 mg 4% DMSO Gel; Etoricoxib 75 mg 4% PG Gel; Etoricoxib 150 mg 4% DMSO Gel; Etoricoxib 150 mg 4% PG Gel; Matching Placebo to Etoricoxib 150 mg 4% DMSO Gel; Matching Placebo to Etoricoxib 150 mg 4% PG Gel

Dermatitis, Atopic, or Eczema, Atopic Clinical Trial using Tofacitinib ointment 20mg/g; Placebo ointment (Vehicle)

Pfizer - Recruiting 18 years to 50 years.
- A Phase 2a, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis.
Tofacitinib ointment 20mg/g; Placebo ointment (Vehicle)

Influenza, or Flu Clinical Trial using Anti-influenza IVIG

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects.
Anti-influenza IVIG

Kidney Failure, Chronic Clinical Trial using ticagrelor

AstraZeneca - Recruiting 18 years to 80 years.
- A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Hemodialyisis Patients to Subjects With Normal Renal Function.
ticagrelor

FGFR Inhibition, Pharmacokinetics, Biomarkers, or ER+ Breast Canc Clinical Trial using AZD4547; Exemestane; Placebo; Fulvestrant

AstraZeneca - Recruiting 18 years or older.
- A Randomised Double-blind Phase IIa Study (With Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW).
AZD4547; Exemestane; Placebo; Fulvestrant

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Clinical Trial using tolvaptan

Otsuka Pharmaceutical Development & Commercialization, Inc. - Recruiting 18 years or older.
- A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion.
tolvaptan

Multiple Myeloma Clinical Trial using 4 mg Oral POM + 40 mg Oral DEX; 2 mg Oral POM + 40 mg Oral DEX

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics (PK) and Safety of Pomalidomide (POM) When Given in Combination With Low Dose Dexamethasone (LD-DEX) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Impaired Renal Function.
4 mg Oral POM + 40 mg Oral DEX; 2 mg Oral POM + 40 mg Oral DEX

Juvenile Idiopathic Arthritis Clinical Trial using CP-690,550

Pfizer - Recruiting 2 years to 18 years.
- An Open-Label Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Pediatric Patients From 2 To Less Than 18 Years Of Age With Juvenile Idiopathic Arthritis (JIA).
CP-690,550

Normal Hepatic Function,, or Impaired Hepatic Function Clinical Trial using LDE225

Novartis - Recruiting 18 years to 65 years.
- A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function..
LDE225

HIV, Atrial Fibrillation, or Venous Thromboembolism Clinical Trial using Ritonavir; Cobicistat

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- The Influence of Cobicistat or Ritonavir on Dabigatran Pharmacokinetics and Pharmacodynamics in Healthy Volunteers.
Ritonavir; Cobicistat

Primary Immune Deficiency Disorders, Common Variable Immunodefici Clinical Trial using Gammaplex (5%); Gammaplex 10

Bio Products Laboratory - Recruiting 2 years to 55 years.
- A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplexr 10 and Gammaplexr 5% in Primary Immunodeficiency Diseases.
Gammaplex (5%); Gammaplex 10

Head and Neck Cancer Clinical Trial using LUZ11

Luzitin SA - Recruiting 18 years or older.
- An Open-label Study to Investigate the Tolerability, Pharmacokinetics and Anti-tumour Effect Following Photodynamic Therapy (PDT) With Single-ascending Doses of LUZ11 in Patients With Advanced Head and Neck Cancer.
LUZ11

ST-segment Elevation Myocardial Infarction Clinical Trial using Placebo; LC28-0126 Dose A; LC28-0126 Dose B; LC28-0126 Dose C

LG Life Sciences - Recruiting 20 years to 75 years.
- A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Single Injection LC28-0126 Immediately Before PCI (Percutaneous Coronary Intervention) in Patients With STEMI(ST-segment Elevation Myocardial Infarction).
Placebo; LC28-0126 Dose A; LC28-0126 Dose B; LC28-0126 Dose C

Healthy Clinical Trial using BIIB061; Placebo; 14C-BIIB061

Biogen Idec - Recruiting 20 years to 55 years.
- A Randomized, Double-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect.
BIIB061; Placebo; 14C-BIIB061

Renal Cell Carcinoma, Breast Cancer, Colon Cancer, Lung Cancer, o Clinical Trial using dimethane sulfonate (DMS612, NSC 281612)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies.
dimethane sulfonate (DMS612, NSC 281612)

Renal Insufficiency, or Renal Impairment Clinical Trial using sugammadex

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency.
sugammadex

Cocaine Use, or Pharmacokinetics Clinical Trial using cocaine; quinine; acetazolamide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- Pharmacodynamic and Pharmacokinetic Interactions Between Intravenous Cocaine and Acetazolamide or Quinine.
cocaine; quinine; acetazolamide

Advanced Metastatic Breast Cancer Clinical Trial using AZD2014; Fulvestrant

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.
AZD2014; Fulvestrant

Congestive Heart Failure Clinical Trial using Oral R,R'-Fenoterol; Oral Racemic Fenoterol

National Institutes of Health Clinical Center (CC) - Recruiting 21 years to 60 years.
- A Study of (R, R') and (S,S': R,R')- Fenoterol: Initial Clinical Evaluation for Pharmacokinetics, Pharmacodynamics, and Safety.
Oral R,R'-Fenoterol; Oral Racemic Fenoterol

Atrial Fibrillation Clinical Trial using Pradaxa, dabigatran etexilate

Boehringer Ingelheim - Recruiting 18 years or older.
- A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy.
Pradaxa, dabigatran etexilate

Influenza Clinical Trial using AVI-7100 versus placebo

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 60 years.
- A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects.
AVI-7100 versus placebo

Tuberculosis Clinical Trial using RIF; INH; PZA; KM; MXF

National Institutes of Health Clinical Center (CC) - Recruiting 20 years or older.
- Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery.
RIF; INH; PZA; KM; MXF

Type 2 Diabetes Mellitus Clinical Trial using Lixisenatide (AVE0010); Placebo

Sanofi - Recruiting 10 years to 65 years.
- A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes.
Lixisenatide (AVE0010); Placebo

Acquired Immune Deficiency Syndrome (AIDS), or HIV Infections Clinical Trial using Elvitegravir; RTV-boosted PI

Gilead Sciences - Recruiting N/A to 17 years.
- A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG)Administered With a Background-Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects.
Elvitegravir; RTV-boosted PI

Heart Failure Clinical Trial using BAY1021189 (1.25 mg); BAY1021189 (5 mg); Placebo

Bayer - Recruiting 18 years or older.
- A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF).
BAY1021189 (1.25 mg); BAY1021189 (5 mg); Placebo

Heart Failure Clinical Trial using BAY1021189 (1.25 mg); BAY1021189 (5 mg); Placebo

Bayer - Recruiting 18 years or older.
- A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF).
BAY1021189 (1.25 mg); BAY1021189 (5 mg); Placebo

Gonococcal (GC) Infection Clinical Trial using Part A; Part B; Part C

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase I, Randomized, Placebo-controlled, Single Center Study to Assess the Safety, Tolerability, and Pharmacokinetic of AZD0914 After Oral Administration of Single Doses or Multiple Doses Over 24 Hours and to Assess the Effect of Food in Healthy Adult Volunteers.
Part A; Part B; Part C

Pharmacokinetics,, Open Label,, CAZ-AVI,, CXL,, Effect on Intesti Clinical Trial using CAZ-AVI; CXL

AstraZeneca - Recruiting 18 years to 45 years.
- A Phase 1, Open-label, Multiple-dose, Single Centre Study to Investigate the Effect of Administration of CAZ-AVI and CXL on the Intestinal Flora of Healthy Volunteers..
CAZ-AVI; CXL

Advanced Solid Malignancy,, Safety and Tolerability,, Pharmacokin Clinical Trial using AZD5363

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Compare Two Dosage Formulations of AZD5363 and to Establish the Effect of Food on the Pharmacokinetic Exposure, Safety and Tolerability of AZD5363 in Patients With Advanced Solid Malignancies.
AZD5363

Healthy Clinical Trial using AZD8848; Placebo

AstraZeneca - Recruiting 18 years to 45 years.
- A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects.
AZD8848; Placebo

Advanced Adult Hepatocellular Carcinoma, or Hepatocellular Carcin Clinical Trial using AZD9150

AstraZeneca - Recruiting 18 years or older.
- A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma.
AZD9150

Solid Tumor Clinical Trial using Oraxol

Kinex Pharmaceuticals Inc - Recruiting 18 years or older.
- A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies.
Oraxol

Neoplasms Clinical Trial using RO6895882

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION, PHASE I STUDY WITH AN EXPANSION PHASE, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6895882, AN IMMUNOCYTOKINE, CONSISTING OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
RO6895882

Healthy Volunteer Clinical Trial using RO6864018

Hoffmann-La Roche - Recruiting 21 years to 65 years.
- A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6864018 FOLLOWING ORAL ADMINISTRATION IN ASIAN HEALTHY SUBJECTS.
RO6864018

Healthy Volunteers Clinical Trial using CANA/MET XR FDC

Janssen Research & Development, LLC - Recruiting 18 years to 55 years.
- An Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics of Canagliflozin (JNJ-28431754) and Metformin Following Once-Daily Administration of 2 Canagliflozin/Metformin XR (150/1,000-mg) Fixed Dose Combination Tablets in Healthy Subjects.
CANA/MET XR FDC

Hemophilia A Clinical Trial using BAY94-9027

Bayer - Recruiting N/A to 12 years.
- A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A.
BAY94-9027

Influenza Clinical Trial using oseltamivir [Tamiflu]

Hoffmann-La Roche - Recruiting N/A to 12 years.
- AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLUr) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMISED CHILDREN, FROM 2 WEEKS TO LESS THAN 13 YEARS OF AGE, WITH CONFIRMED INFLUENZA INFECTION.
oseltamivir [Tamiflu]

Diabetes Mellitus, Type 2 Clinical Trial using PF-06291874; Placebo

Pfizer - Recruiting 18 years to 70 years.
- A Phase 1, Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of PF-06291874 In Adults With Type 2 Diabetes Mellitus.
PF-06291874; Placebo

Bacterial Infections Clinical Trial using Solithromycin

Cempra Pharmaceuticals - Recruiting 12 years to 17 years.
- A Phase 1, Open-label, Multi-center Study to Determine the PK and Safety of Solithromycin as Add-on Therapy in Adolescents With Suspected or Confirmed Bacterial Infection.
Solithromycin

Neoplasms Clinical Trial using Regorafenib (Stivarga, BAY73-4506)

Bayer - Recruiting 18 years or older.
- A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group.
Regorafenib (Stivarga, BAY73-4506)

Lymphoblastic Leukemia, Acute T-cell, or Precursor T-Cell Lymphob Clinical Trial using BMS-906024; Dexamethasone

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.
BMS-906024; Dexamethasone

Antithrombin III Deficiency Clinical Trial using Plasma-derived AT-III concentrate

Grifols Biologicals Inc. - Recruiting 12 years or older.
- A Phase II/III Pivotal Trial Evaluating the Safety, Pharmacokinetic Properties and Efficacy of a Plasma-Derived Anti-thrombin III Concentrate With Administration in Surgery, Pregnancy and Thromboembolic or Thrombotic Events..
Plasma-derived AT-III concentrate

Healthy Clinical Trial using JNJ-42165279; Itraconazole

Janssen Pharmaceutica N.V., Belgium - Recruiting 18 years to 55 years.
- A Study to Investigate the Potential Effects of Repeated Administration of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Subjects.
JNJ-42165279; Itraconazole

Osteoporosis Clinical Trial using Odanacatib; Placebo

Merck Sharp & Dohme Corp. - Recruiting 12 years to 25 years.
- A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents and Young Adults Treated With Glucocorticoids.
Odanacatib; Placebo

Advanced Castrate-resistant Prostate Cancer (CRPC);, Squamous Non Clinical Trial using AZD8186

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186 Within Prospectively-validated PTEN Deficient Tumours.
AZD8186

Cystic Fibrosis Clinical Trial using CTX-4430; Mannitol; Placebo

Celtaxsys, Inc. - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days.
CTX-4430; Mannitol; Placebo

Depressive Disorder, or Lactation Clinical Trial using SSRI/SNRI

Centre Hospitalier Universitaire Vaudois - Recruiting 18 years or older.
- Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child.
SSRI/SNRI

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; tizanidine

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, 3- PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF SINGLE DOSE OF TIZANIDINE (A CYP1A2 SUBSTRATE) IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; tizanidine

Neoplasms, or Lymphoma Clinical Trial using Part 1: JNJ-42756493; Part 2: JNJ-42756493

Janssen Research & Development, LLC - Recruiting 20 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
Part 1: JNJ-42756493; Part 2: JNJ-42756493

Pneumonia, Pneumococcal Infection, or Pathogen Resistance Clinical Trial using Colistimethate (Colistin)Sodium-Intravenous; Colistimethate (Colistin)Sodium-Aerosolized

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 45 years.
- A Phase 1, Open-Labeled Study of the Safety, Tolerability and Pharmacokinetics of Aerosolized Colistimethate Sodium After Multiple Doses Administered Separately or in Combination With Intravenous Colistimethate Sodium in Healthy Adults.
Colistimethate (Colistin)Sodium-Intravenous; Colistimethate (Colistin)Sodium-Aerosolized

Arthritis, Juvenile Rheumatoid Clinical Trial using Sulfasalazine

Pfizer - Recruiting 6 years to 17 years.
- An Open Label Non-Randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis.
Sulfasalazine

Advanced Non Small Cell Lung Cancer, or Advanced (Inoperable) Non Clinical Trial using AZD9291

AstraZeneca - Recruiting 18 years or older.
- Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent.
AZD9291

Solid Tumours Clinical Trial using Olaparib tablet dosing

AstraZeneca - Recruiting 18 years to 75 years.
- An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment.
Olaparib tablet dosing

Solid Tumours Clinical Trial using Pharmacokinetic sampling; Rifampicin; Olaparib tablet dosing

AstraZeneca - Recruiting 18 years or older.
- A Non-randomised, Open-label, Sequential, Multicentre, Two-part, Phase I Study to Assess the Effect of Rifampicin, a CYP Inducer, on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours.
Pharmacokinetic sampling; Rifampicin; Olaparib tablet dosing

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN9708

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1 Study of [14C]-MLN9708 to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas.
MLN9708

Lung Cancer, Small Cell Clinical Trial using GSK2879552

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma.
GSK2879552

Anaemia Clinical Trial using GSK1278863; Placebo

GlaxoSmithKline - Recruiting 20 years or older.
- A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease.
GSK1278863; Placebo

Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinet Clinical Trial using AZD5363

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies..
AZD5363

Cancer Clinical Trial using Part 1 Cohort 1: Dabrafenib plus Panitumumab; Part 1 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Part 1 Cohort 3A: Dabrafenib plus Trametinib plus Panitumumab; Part 1 Cohort 3B: Dabrafenib plus Trametinib plus Panitumumab; Part 1 Cohort 4: Dabrafenib plus Trametinib plus Panitumumab; Part 2 Cohort 1: Dabrafenib plus Panitumumab; Part 2 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Part 3 Cohort 1: Dabrafenib plus Panitumumab; Part 3 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Part 3 Cohort 3: 5-fluorouracil-based chemotherapy

GlaxoSmithKline - Recruiting 18 years or older.
- An Open-Label, Three-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E or V600K Positive Colorectal Cancer.
Part 1 Cohort 1: Dabrafenib plus Panitumumab; Part 1 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Part 1 Cohort 3A: Dabrafenib plus Trametinib plus Panitumumab; Part 1 Cohort 3B: Dabrafenib plus Trametinib plus Panitumumab; Part 1 Cohort 4: Dabrafenib plus Trametinib plus Panitumumab; Part 2 Cohort 1: Dabrafenib plus Panitumumab; Part 2 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Part 3 Cohort 1: Dabrafenib plus Panitumumab; Part 3 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab; Part 3 Cohort 3: 5-fluorouracil-based chemotherapy

Pulmonary Disease, Chronic Obstructive Clinical Trial using GSK2256294

GlaxoSmithKline - Recruiting 18 years or older.
- A Study to Evaluate the Effect of Age, Food and Gender on Tolerability and Pharmacokinetics of GSK2256294 Following a Single Oral Administration in Healthy Fed and Fasted Elderly Subjects. This Study Will Also Evaluate the Biliary Metabolites in Healthy Young Males Following a Single Dose of GSK2256294.
GSK2256294

Hepatitis C Clinical Trial using Peginterferon lambda

Nanogen Pharmaceutical Biotechnology Co., Ltd - Recruiting 18 years to 65 years.
- The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients.
Peginterferon lambda

Lung Injury, Acute Clinical Trial using Dose 1 GSK2586881; Dose 2 GSK2586881; Dose 3 GSK2586881; Dose 4 GSK2586881; Placebo (saline)

GlaxoSmithKline - Recruiting 18 years to 80 years.
- A Two Part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2586881 in Patients With Acute Lung Injury.
Dose 1 GSK2586881; Dose 2 GSK2586881; Dose 3 GSK2586881; Dose 4 GSK2586881; Placebo (saline)

Alzheimer's Disease Clinical Trial using Oxaloacetate (OAA)

University of Kansas - Recruiting 18 years or older.
- Oxaloacetate Pharmacokinetics and Safety.
Oxaloacetate (OAA)

Healthy Clinical Trial using ARC-520; Placebo

Arrowhead Research Corporation - Recruiting 18 years to 55 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers.
ARC-520; Placebo

Stomach Neoplasms Clinical Trial using AMG 337

Amgen - Recruiting 18 years or older.
- A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors.
AMG 337

Solid Tumours Clinical Trial using Olaparib tablets; Pharmacokinetic sampling; Dietary Fasted; Dietary High Fat

AstraZeneca - Recruiting 18 years or older.
- A Randomised, Open-label, Three-part, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours.
Olaparib tablets; Pharmacokinetic sampling; Dietary Fasted; Dietary High Fat

Cystic Fibrosis Clinical Trial using VX-809; VX-770; VX-809 placebo; VX-770 placebo

Vertex Pharmaceuticals Incorporated - Recruiting 18 years or older.
- A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation.
VX-809; VX-770; VX-809 placebo; VX-770 placebo

Pneumonia, Bacterial Clinical Trial using Ciprofloxacin (Cipro, BAYQ3939)

Bayer - Recruiting 20 years or older.
- A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and 400 mg TID) in Hospitalized Patients With Severe Bacterial Pneumonia or Bacterial Pneumonia With a Poor Response to Other Antimicrobials.
Ciprofloxacin (Cipro, BAYQ3939)

Solid Tumours Clinical Trial using Olaparib tablet dosing

AstraZeneca - Recruiting 18 years to 75 years.
- An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study of the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Renal Function or Renal Impairment.
Olaparib tablet dosing

Type 2 Diabetes Mellitus Clinical Trial using Sitagliptin/metformin XR; Placebo

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets.
Sitagliptin/metformin XR; Placebo

Hepatitis C, Liver Disease Clinical Trial using DEB025 200mg; DEB025 300mg; DEB025 400mg

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment na‹ve Patients.
DEB025 200mg; DEB025 300mg; DEB025 400mg

Psoriasis Vulgaris, or Psoriasis Clinical Trial using tofacitinib ointment 20 mg/g; tofacitinib ointment 10 mg/g; placebo ointment (vehicle)

Pfizer - Recruiting 18 years or older.
- A Phase 2b, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.
tofacitinib ointment 20 mg/g; tofacitinib ointment 10 mg/g; placebo ointment (vehicle)

Asthma Clinical Trial using AMG 282; AMG 282 Matching Placebo

Amgen - Recruiting 18 years to 45 years.
- A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma.
AMG 282; AMG 282 Matching Placebo

Neoplasms Clinical Trial using BAY1163877

Bayer - Recruiting 18 years or older.
- An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors.
BAY1163877

Pemphigus Vulgaris Clinical Trial using VAY736; Placebo to VAY736

Novartis - Recruiting 20 years to 70 years.
- A Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus Vulgaris.
VAY736; Placebo to VAY736

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC).
selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

Oncology Clinical Trial using BAY94-9343; BAY94-9343 (Expansion); BAY94-9343 (1.8 mg/kg); BAY94-9343 (2.2 mg/kg)

Bayer - Recruiting 18 years or older.
- An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors.
BAY94-9343; BAY94-9343 (Expansion); BAY94-9343 (1.8 mg/kg); BAY94-9343 (2.2 mg/kg)

Cure Rate Clinical Trial using KAE609

Novartis - Recruiting 20 years to 60 years.
- An Open Label, Single Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum Malaria Mono-infection.
KAE609

Acute Respiratory Insufficiency, Chronic Respiratory Insufficienc Clinical Trial using Nebulizer

University Hospital St Luc, Brussels - Recruiting 18 years or older.
- Comparison of Pharmacokinetics of Amikacin Administered by Three Vibrating Mesh Nebulizers in Healthy Volunteers.
Nebulizer

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN8237

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas.
MLN8237

Stroke Clinical Trial using JPI-289; Placebo

Jeil Pharmaceutical Co., Ltd. - Recruiting 19 years to 55 years.
- A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled,Single Dose, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of JPI-289 in Healthy Male Subjects..
JPI-289; Placebo

Solid Tumors, or Lymphoma Clinical Trial using alisertib; esomeprazole; rifampin

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas.
alisertib; esomeprazole; rifampin

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; phenprocoumon

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, RANDOMINZED, PARALELL STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF PHENPROCOUMON IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; phenprocoumon

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; digoxin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.
vemurafenib; digoxin

Prostate Cancer Clinical Trial using DSTP3086S

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer.
DSTP3086S

Breast Neoplasms Clinical Trial using Sorafenib (Nexavar, BAY43-9006); Eribulin

Bayer - Recruiting 18 years or older.
- A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors.
Sorafenib (Nexavar, BAY43-9006); Eribulin

Healthy Clinical Trial using PF-06263726; Placebo

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Randomized, Third-Party Open, Placebo-Controlled, Multiple Dose Escalation, Parallel Group Study To Evaluate Local Tolerability, Safety And Pharmacokinetics Of Topically Applied PF-06263276 In Healthy Subjects.
PF-06263726; Placebo

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial using AZD4721; Placebo; AZD5069

AstraZeneca - Recruiting 18 years to 50 years.
- A Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4721 After Once Daily Administration of Multiple Ascending Doses for 10 Days, and an Open-label Comparison With the Pharmacodynamics of AZD5069 Given Twice Daily for 3 Days.
AZD4721; Placebo; AZD5069

Safety,, Tolerability,, or Healthy Subjects Clinical Trial using AZD8848; Placebo to match AZD8848

AstraZeneca - Recruiting 18 years to 50 years.
- A Phase 1, Single Centre, Double-blind, Randomised, Placebo-controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Administration of Multiple Ascending (MAD) Once Weekly Inhaled Doses of AZD8848 in Healthy Subjects.
AZD8848; Placebo to match AZD8848

Hyperphosphataemia in Chronic Kidney Disease Clinical Trial using Lanthanum carbonate; Calcium carbonate

Shire Development LLC - Recruiting 6 Months to 17 years.
- A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate Using a Crossover Design and Investigate the Efficacy and Safety of 12 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 6 Months to <18 Years With Chronic Kidney Disease on Dialysis.
Lanthanum carbonate; Calcium carbonate

Chronic Hepatitis C Infection Clinical Trial using JNJ-47910382 30 mg; JNJ-47910382 90 mg; JNJ-47910382 200 mg; Placebo

Janssen R&D Ireland - Recruiting 18 years to 70 years.
- A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Asian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens.
JNJ-47910382 30 mg; JNJ-47910382 90 mg; JNJ-47910382 200 mg; Placebo

General Anesthesia Clinical Trial using Remimazolam; Propofol; Sevoflurane; Remifentanil; Fentanyl; Rocuronium

Paion UK Ltd. - Recruiting 18 years or older.
- A Randomized, Single-blind Phase II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the PACU/ICU.
Remimazolam; Propofol; Sevoflurane; Remifentanil; Fentanyl; Rocuronium

Transfusional Iron Overload, or Beta-Thalassemia Clinical Trial using SPD602 (SSP-004184)

Shire Development LLC - Recruiting 6 years to 17 years.
- A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload.
SPD602 (SSP-004184)

Healthy, or Hepatic Impairment Clinical Trial using cabozantinib

Exelixis - Recruiting 18 years to 70 years.
- A Phase I, Open-Label, Parallel-Group, Single-Dose Study to Assess the Pharmacokinetics of XL184 (Cabozantinib) Capsules in Hepatic Impaired Adult Subjects.
cabozantinib

Advanced Solid Tumors Clinical Trial using MEDI4736

AstraZeneca - Recruiting 20 years or older.
- A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Japanese Patients With Advanced Solid Tumors.
MEDI4736

Migraine Clinical Trial using PF-05180999; Placebo; 120 mg MR PF-05180999; 360 mg MR PF-05180999; 10 mg cetirizine

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Placebo-Controlled, Crossover, Subject- And Investigator-Blind, Sponsor-Open Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of A Modified-Release Formulation Of PF-05180999 In Healthy Adult Subjects.
PF-05180999; Placebo; 120 mg MR PF-05180999; 360 mg MR PF-05180999; 10 mg cetirizine

Venous Thrombosis, or Pediatrics Clinical Trial using Rivaroxaban (Xarelto, BAY59-7939)

Bayer - Recruiting 6 Months to 18 years.
- Single-dose Pilot Study of Oral Rivaroxaban in Pediatric Subjects With Venous Thromboembolism.
Rivaroxaban (Xarelto, BAY59-7939)

Healthy Clinical Trial using BI 695501; adalimumab-EU source; adalimumab-US source

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years to 55 years.
- Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Double-blind, Single Dose, Parallel-arm, Active Comparator Clinical Phase I Study.
BI 695501; adalimumab-EU source; adalimumab-US source

Hyperlipidemia, Hypercholesterolemia, or Dyslipidemia Clinical Trial

Ohio State University - Recruiting 18 years or older.
- An Observational Study Investigating Genetic Influences on Statin Plasma Concentrations in Adults Taking Atorvastatin, Simvastatin, or Lovastatin.

Congenital Bleeding Disorder, or Haemophilia A Clinical Trial using NNC 0129-0000-1003

Novo Nordisk - Recruiting N/A to 11 years.
- A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A.
NNC 0129-0000-1003

Heart Failure Clinical Trial using BAY1067197 (10 mg); BAY1067197; Placebo (10 mg); Placebo

Bayer - Recruiting 18 years to 75 years.
- A Double Blinded, Placebo Controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Acute Cardiovascular Responses of a 7 Day Oral Treatment With the Partial Adenosine A1 Receptor Agonist BAY1067197 in Patients With Chronic Systolic Heart Failure: the PARSiFAL-pilot Study..
BAY1067197 (10 mg); BAY1067197; Placebo (10 mg); Placebo

Dental Pain Clinical Trial using Acetaminophen ER; Placebo

Johnson & Johnson Consumer and Personal Products Worldwide - Recruiting 18 years to 45 years.
- A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Efficacy, Safety, and Pharmacokinetics Study of Extended-Release (ER) Acetaminophen in Postoperative Dental Pain.
Acetaminophen ER; Placebo

Hepatitis C Clinical Trial using TD-6450; Placebo

Theravance, Inc. - Recruiting 18 years to 60 years.
- A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects.
TD-6450; Placebo

Neoplasms Clinical Trial using BAY1082439

Bayer - Recruiting 21 years or older.
- An Open Label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1082439 Given Once Daily in Subjects With Advanced Malignancies.
BAY1082439

Solid Tumors Clinical Trial using MK-8242

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors.
MK-8242

Acute Myeloid Leukemia Clinical Trial using AZD1208

AstraZeneca - Recruiting 18 years or older.
- A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML).
AZD1208

Advanced Malignant Glioma, Anaplastic Astrocytomas, or Glioblasto Clinical Trial using AMG 595

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
AMG 595

Prostate Cancer Clinical Trial using Sulforadex; alpha-cyclodextrin

Evgen Pharma - Recruiting 18 years to 45 years.
- A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadexr in Healthy Male Subjects Following Daily Dosing for 7 Days.
Sulforadex; alpha-cyclodextrin

Cutaneous Leishmaniasis Clinical Trial using Topical Amphotericin B at 3%

Drugs for Neglected Diseases - Recruiting 18 years to 60 years.
- Safety, Pharmacokinetics, and Efficacy of Topical 3% Amphotericin B Cream for the Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia.
Topical Amphotericin B at 3%

Various Advanced Cancer Clinical Trial using BMS-986115

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors.
BMS-986115

Pulmonary Arterial Hypertension Clinical Trial using MK-8892; Placebo for MK-8892

Merck Sharp & Dohme Corp. - Recruiting 18 years to 70 years.
- A 28-Day Multiple-Dose Titration Study to Assess the Effects of MK-8892 on Safety, Tolerability and Pharmacokinetics in Subjects With Pulmonary Arterial Hypertension.
MK-8892; Placebo for MK-8892

Solid Tumours Clinical Trial using selumetinib (oral)

AstraZeneca - Recruiting 18 years to 45 years.
- A Phase I, Randomized, Open-label, Single-center, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Aged 18 to 45 Years.
selumetinib (oral)

X-Linked Hypohidrotic Ectodermal Dysplasia Clinical Trial using EDI200

Edimer Pharmaceuticals - Recruiting N/A to 14 Days.
- A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED).
EDI200

Acquired Immune Deficiency Syndrome (AIDS), or HIV Infections Clinical Trial using ATV; DRV; Cobicistat; Background regimen

Gilead Sciences - Recruiting 3 Months to 17 years.
- A Phase 2/3, Multicenter, Open-label, Multicohort, Two-Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered With Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects.
ATV; DRV; Cobicistat; Background regimen

Safety, Tolerability, Pharmacokinetics, or Cancer Clinical Trial using Dexanabinol; Placebo

e-Therapeutics PLC - Recruiting 18 years to 45 years.
- Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects.
Dexanabinol; Placebo

Parkinson's Disease Clinical Trial using LY03003; Neupro

Luye Pharma Group Ltd. - Recruiting 18 years or older.
- A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections.
LY03003; Neupro

Wegener's Granulomatosis, Microscopic Polyangiitis Clinical Trial using rituximab [MabThera/Rituxan]

Hoffmann-La Roche - Recruiting 2 years to 17 years.
- A PHASE IIa, INTERNATIONAL, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF 4 x 375 mg/m2 INTRAVENOUS RITUXIMAB IN PEDIATRIC PATIENTS WITH SEVERE GRANULOMATOSIS WITH POLYANGIITIS (WEGENER S) OR MICROSCOPIC POLYANGIITIS.
rituximab [MabThera/Rituxan]

Cardiac Arrest, or Hypothermia Clinical Trial

Children's Hospital of Philadelphia - Recruiting N/A to 17 years.
- Impact of Hypothermia on Midazolam and Morphine Pharmacokinetics.

Part 1 - Healthy Volunteers, or Part 2 - Patients With Hypertensi Clinical Trial using LFF269; Placebo to LFF269

Novartis - Recruiting 18 years to 80 years.
- A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects.
LFF269; Placebo to LFF269

TTR-mediated Amyloidosis Clinical Trial using ALN-TTR02 administered by intravenous (IV) infusion

Alnylam Pharmaceuticals - Recruiting 18 years to 85 years.
- A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02.
ALN-TTR02 administered by intravenous (IV) infusion

Neoplasms Clinical Trial using ZSTK474

Zenyaku Kogyo Co., Ltd. - Recruiting 20 years or older.
- A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients With Advanced Solid Malignancies.
ZSTK474

Rheumatoid Arthritis Clinical Trial using SAN-300; Placebo

Santarus - Recruiting 18 years to 75 years.
- A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s)..
SAN-300; Placebo

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using nanosomal docetaxel lipid suspension; pharmacological study

USC/Norris Comprehensive Cancer Center - Recruiting 18 years to 64 years.
- An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors.
nanosomal docetaxel lipid suspension; pharmacological study

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma Clinical Trial using Urelumab (BMS-663513)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL).
Urelumab (BMS-663513)

Chemotherapy Induced Nausea and Vomiting Clinical Trial using granisetron transdermal system; Granisetron IV

Prostrakan Pharmaceuticals - Recruiting 13 years to 17 years.
- An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancusor Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years).
granisetron transdermal system; Granisetron IV

Psoriasis Clinical Trial using ASKP1240; Placebo

Astellas Pharma Inc - Recruiting 18 years to 75 years.
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis.
ASKP1240; Placebo

Anemia, or Chronic Kidney Disease Clinical Trial using Darbepoetin alfa

Amgen - Recruiting N/A to 1 year.
- An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin Alfa in Paediatric Subjects From Birth to Less Than 1 Year of Age With Anemia Due to Chronic Kidney Disease.
Darbepoetin alfa

Cough Clinical Trial using GSK2339345; Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Randomised, Double-Blind (Sponsor-Unblind), Placebo Controlled, Cross-Over Study to Investigate the Efficacy, Effect on Cough Reflex Sensitivity, Safety, Tolerability and Pharmacokinetics of Inhaled GSK2339345 in Patients With Chronic Idiopathic Cough Using an Aqueous Droplet Inhaler.
GSK2339345; Placebo

Iron Deficiency Anemia Clinical Trial using Tardyferon 80 mg

Pierre Fabre Medicament - Recruiting 18 years to 45 years.
- Study of the Pharmacokinetics of Serum Iron After Single Oral Administration of Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia.
Tardyferon 80 mg

Immune Thrombocytopenia Purpura Clinical Trial using MK-8723; Matching Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- A Two-Part, Single Rising Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MK-8723 in Healthy Adults and Patients With Immune Thrombocytopenia Purpura.
MK-8723; Matching Placebo

Lupus Arthritis, Systemic Lupus Erythematosus Clinical Trial using AMG 557; Matching Placebo

Amgen - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis.
AMG 557; Matching Placebo

Hepatitis C Virus Clinical Trial using GS-5816

Gilead Sciences - Recruiting 18 years to 79 years.
- A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment.
GS-5816

Alzheimer's Disease Clinical Trial using TPI-287 2 mg/m2; TPI-287 6.3 mg/m2; TPI-287 20 mg/m2; Placebo

University of California, San Francisco - Recruiting 50 years to 82 years.
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI-287 in Patients With Mild to Moderate Alzheimer's Disease.
TPI-287 2 mg/m2; TPI-287 6.3 mg/m2; TPI-287 20 mg/m2; Placebo

Hemophilia A Clinical Trial using Moroctocog alfa (AF-CC)

Pfizer - Recruiting N/A to 6 years.
- An Open-Label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics (PK) Of B Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog Alfa [AF-CC]) In Children With Hemophilia A.
Moroctocog alfa (AF-CC)

Hemophilia A Clinical Trial using Moroctocog alfa ( AF-CC); Laboratory tests

Pfizer - Recruiting N/A to 11 years.
- A Non-Randomized, Open-Label Study To Evaluate The Pharmacokinetics, Safety, And Efficacy Of ReFacto AF In Previously Treated Pediatric Subjects Less Than Twelve Years Of Age With Severe Hemophilia A (FVIII:C <1%).
Moroctocog alfa ( AF-CC); Laboratory tests

Liver Cancer Clinical Trial using onartuzumab; sorafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB GIVEN AS A SINGLE AGENT AND IN COMBINATION WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC).
onartuzumab; sorafenib

Healthy Volunteer Clinical Trial using Posaconozole; RO5424802

Hoffmann-La Roche - Recruiting 18 years to 55 years.
- An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects.
Posaconozole; RO5424802

Schizophrenia Clinical Trial using RO5545965; Placebo; risperidone

Hoffmann-La Roche - Recruiting 18 years to 60 years.
- A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT-BLIND, MULTIPLE-DOSE, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO5545965 IN PATIENTS WITH SCHIZOPHRENIA ON RISPERIDONE..
RO5545965; Placebo; risperidone

Neoplasms Clinical Trial using vemurafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients.
vemurafenib

Healthy Volunteer Clinical Trial using RO6870868; placebo

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacodynamics and the Effect of Food on the Pharmacokinetics of RO6870868.
RO6870868; placebo

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; rifampin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Rifampin On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib.
vemurafenib; rifampin

Healthy Volunteer Clinical Trial using RO5545965; placebo

Hoffmann-La Roche - Recruiting 18 years to 64 years.
- A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects..
RO5545965; placebo

Neoplasm Malignant Clinical Trial using SAR405838

Sanofi - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients With Advanced Cancer.
SAR405838

HIV Infection, Monoclonal Antibody, Human, HIV Antibodies, VRC01 Clinical Trial using VRC-HIVMAB060-00-AB

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- VRC 602: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIV MAB060-00-AB (VRC01),Administered Intravenously or Subcutaneously to Healthy Adults.
VRC-HIVMAB060-00-AB

Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy.
Nivolumab

Stable Renal Transplant Patients Clinical Trial using Tacrolimus

Veloxis Pharmaceuticals - Recruiting 18 years to 70 years.
- Prospective, Randomized, Open-label, Single-center, Two Sequence, Three Period Crossover Study to Compare the Steady State Pharmacokinetics of Once-Daily-Extended Release Melt Dose Tacrolimus Tablets (LCP-Tacro) to Generic Tacrolimus Capsules Twice Daily in Stable African American Renal Transplant Patients..
Tacrolimus

Overweight, Obesity, Type 2 Diabetes Mellitus Clinical Trial using AZP-531

Aliz‚ Pharma - Recruiting 18 years to 50 years.
- A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus.
AZP-531

Constipation - Functional Clinical Trial using Lubiprostone; Placebo

Sucampo Pharma Americas, LLC - Recruiting 6 years to 17 years.
- A Multicentre, Randomised, Placebo-controlled, Double-blind Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ò 6 Years to < 18 Years With Functional Constipation.
Lubiprostone; Placebo

Ebola Virus Infection Clinical Trial using TKM-100802 for Injection; Placebo

Tekmira Pharmaceuticals Corporation - Recruiting 18 years to 50 years.
- A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With Additional Multiple-Ascending Dose Cohorts to Evaluate the Safety, Tolerability, and Pharmacokinetics of TKM-100802 in Healthy Human Volunteers.
TKM-100802 for Injection; Placebo

Type 2 Diabetes Mellitus Clinical Trial using LY3053102; Exenatide extended release; Placebo

Eli Lilly and Company - Recruiting 21 years or older.
- Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus.
LY3053102; Exenatide extended release; Placebo

Advanced Solid Tumors Clinical Trial using MP-3549.1

Mallinckrodt - Recruiting 18 years or older.
- A Multicenter, Open-Label, Phase 1 First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous MP-3549.1 in Subjects With Advanced Solid Tumors.
MP-3549.1

Safety and Tolerability of Iloperidone Clinical Trial using iloperidone (oral tablet)

Novartis - Recruiting 12 years to 17 years.
- A Multicenter, Open-label, Sequential Cohort, Dose-escalation, 14-day Study to Explore the Tolerability and Pharmacokinetics of Iloperidone 12 to 24 mg/Day Followed by 26 Weeks of Flexible Dosing (6 to 24 mg/Day) in Adolescent Patients (Aged 12 to 17 Years).
iloperidone (oral tablet)

Healthy Clinical Trial using 100 mg CNTO 3157; 300 mg CNTO 3157; 600 mg CNTO 3157; 300 mg CNTO 3157; Placebo

Janssen Research & Development, LLC - Recruiting 18 years to 55 years.
- A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of CNTO3157 Following an Escalating Single SC Dose to Healthy Japanese and Caucasian Subjects or a Single Intravenous Dose to Healthy Caucasian Subjects.
100 mg CNTO 3157; 300 mg CNTO 3157; 600 mg CNTO 3157; 300 mg CNTO 3157; Placebo

Malignant Tumors Clinical Trial using Gemcitabine HCl Oral Formulation

InnoPharmax Inc. - Recruiting 18 years or older.
- An Open-Label, Exploratory, Limited Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors.
Gemcitabine HCl Oral Formulation

Advanced Solid Malignancies, or Malignant Lymphomas Clinical Trial using Gemcitabine HCl Oral Formulation

InnoPharmax Inc. - Recruiting 20 years or older.
- An Open Label, Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of Gemcitabine Hydrochloride Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas.
Gemcitabine HCl Oral Formulation

Neoplasms, Brain Clinical Trial using Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

GlaxoSmithKline - Recruiting 1 Month to 17 years.
- Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation Positive Solid Tumors.
Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

Arthritis, Rheumatoid Clinical Trial using CHR-5154; Placebo

GlaxoSmithKline - Recruiting 18 years to 45 years.
- A Phase 1 Double-blind, Randomised, Placebo-controlled, Dose Escalating Study to Assess the Safety and Tolerability of Single and Multiple Oral Doses of CHR-5154 and the Effect of the Fasted and Fed State on Pharmacokinetics of CHR-5154 and CHR-5426 in Healthy Male Volunteers.
CHR-5154; Placebo

Malaria Clinical Trial using KAF156 400 mg; KAF156 800 mg

Novartis - Recruiting 20 years to 60 years.
- A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection.
KAF156 400 mg; KAF156 800 mg

Cancer Clinical Trial using Dabrafenib 150 mg twice a day (BID); Rabeprazole 40 mg once daily (OD); Rifampin 600 mg OD

GlaxoSmithKline - Recruiting 18 years or older.
- An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects With BRAF V600 Mutation Positive Tumors.
Dabrafenib 150 mg twice a day (BID); Rabeprazole 40 mg once daily (OD); Rifampin 600 mg OD

Crohn's Disease Clinical Trial using Adalimumab

AbbVie - Recruiting 18 years to 70 years.
- A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Two Adalimumab Dosing Regimens in Chinese Subjects With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein.
Adalimumab

Neoplasms Clinical Trial using Regorafenib (Stivarga, BAY73-4506); Cetuximab (ERBITUX)

Bayer - Recruiting 18 years or older.
- A Phase 1b, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY73-4506) in Combination With Cetuximab in Subjects With Locally Advanced or Metastatic Solid Tumors Who Are Not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as a Standard Treatment.
Regorafenib (Stivarga, BAY73-4506); Cetuximab (ERBITUX)

Gastroparesis Clinical Trial using GSK962040 (25 mg tablet); Placebo

GlaxoSmithKline - Recruiting 40 years to 80 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying.
GSK962040 (25 mg tablet); Placebo

Healthy Clinical Trial using E2006 2.5 mg; E2006 10 mg; E2006 25 mg; Placebo

Eisai Inc. - Recruiting 20 years to 55 years.
- A Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects.
E2006 2.5 mg; E2006 10 mg; E2006 25 mg; Placebo

Thrombocytopenia Clinical Trial using avatrombopag

Eisai Inc. - Recruiting 20 years to 55 years.
- .
avatrombopag

Neoplasm Malignant Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma.
SAR245409

Psoriasis Clinical Trial using Brodalumab

Amgen - Recruiting 18 years to 75 years.
- An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque Psoriasis.
Brodalumab

Healthy Japanese Young and Elderly Male and Non-fertile Female Vo Clinical Trial using AZD3293; Placebo

AstraZeneca - Recruiting 20 years to 80 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Healthy Japanese Male and Non-Fertile Female Volunteers Including Elderly.
AZD3293; Placebo

Opioid Related Disorder Clinical Trial using RBP-6000; Subutex

Reckitt Benckiser Pharmaceuticals Inc. - Recruiting 18 years to 65 years.
- An Open-Label, Multicenter, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine (RBP-6000) in Treatment Seeking Opioid-Dependent Subjects.
RBP-6000; Subutex

HCV Infection Clinical Trial using MK-8876 200 mg or ó800 mg

Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years.
- A Multiple Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-8876 in Hepatitis C Patients.
MK-8876 200 mg or ó800 mg

Pharmacokinetics, or Voriconazole Clinical Trial using Midazolam/Ranitidine/Esomeprazole

Children's Hospital Los Angeles - Recruiting N/A to 18 years.
- Ontogeny of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents.
Midazolam/Ranitidine/Esomeprazole

Healthy Clinical Trial using BI 655064; Placebo

Boehringer Ingelheim Pharmaceuticals - Recruiting 20 years to 45 years.
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebocontrolled Within Dose Groups, Clinical Phase I Study).
BI 655064; Placebo

Healthy Volunteers, or Pharmacologic Action Clinical Trial using Group 1 AZD3293; Group 2 AZD3293; Group 3 AZD3293; Group 1 Itraconazole; Group 2 Diltiazem; Group 3 Midazolam

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase I, Single-center, Open-label, 3-group, Fixed-sequence Study to Assess the Effect of Itraconazole, a Potent CYP3A4 Inhibitor, or Diltiazem, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a CYP3A4/CYP3A5 Substrate, in Healthy Young Male and Female Volunteers.
Group 1 AZD3293; Group 2 AZD3293; Group 3 AZD3293; Group 1 Itraconazole; Group 2 Diltiazem; Group 3 Midazolam

Healthy Clinical Trial using JNJ-42721458 (single dose); JNJ-42721458 (multiple doses); Placebo (single dose); Placebo (multiple doses)

Janssen Research & Development, LLC - Recruiting 18 years to 55 years.
- A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single- and Multiple-Doses of JNJ-42721458 in Healthy Male Subjects.
JNJ-42721458 (single dose); JNJ-42721458 (multiple doses); Placebo (single dose); Placebo (multiple doses)

Healthy Volunteers Clinical Trial using RDC5

Chronos Therapeutics Ltd - Recruiting 18 years to 55 years.
- A Phase I, Open-label, Randomised, 3-way Crossover Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of RDC5 Given as a Single Dose to Healthy Volunteers.
RDC5